Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.

<h4>Purpose</h4>Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regimens. We aimed to evaluate the efficacy and safety of S-1-based therapy versus capecitabine -based therapy in gastrointestinal cancers.<h4>Methods</h4>Eligible st...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xunlei Zhang, Chunxiang Cao, Qi Zhang, Yi Chen, Dongying Gu, Yunzhu Shen, Yongling Gong, Jinfei Chen, Cuiju Tang
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/05848c7d9c454236951e81ce1291e9c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05848c7d9c454236951e81ce1291e9c5
record_format	dspace
spelling	oai:doaj.org-article:05848c7d9c454236951e81ce1291e9c52021-11-18T08:39:07ZComparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.1932-620310.1371/journal.pone.0084230https://doaj.org/article/05848c7d9c454236951e81ce1291e9c52014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24392116/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Purpose</h4>Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regimens. We aimed to evaluate the efficacy and safety of S-1-based therapy versus capecitabine -based therapy in gastrointestinal cancers.<h4>Methods</h4>Eligible studies were identified from Pubmed, EMBASE. Additionally, abstracts presented at American Society of Clinical Oncology (ASCO) conferences held between 2000 and 2013 were searched to identify relevant clinical trials. The outcome included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR) and advent events.<h4>Results</h4>A total of 6 studies (4 RCTs and 2 retrospective analysis studies) containing 790 participants were included in this meta-analysis, including 401 patients in the S-1-based group and 389 patients in the capecitabine-based group. Results of our meta-analysis indicated that S-1-based and capecitabine-based regimens showed very similar efficacy in terms of PFS (HR 0.92, 95% CI 0.78-1.09, P = 0.360), OS (HR 1.01, 95% CI 0.84-1.21, P = 0.949), ORR (HR 1.04, 95% CI 0.87-1.25, P = 0.683) and DCR (HR 1.02, 95% CI 0.94-1.10, P = 0.639). There was also no significant difference in toxicity between regimens other than mild more hand-foot syndrome in capecitabine-based regimens.<h4>Conclusion</h4>Both the S-1-based and capecitabine-based regimens are equally active and well tolerated, and have the potential of backbone chemotherapy regimen in further studies of gastrointestinal cancers.Xunlei ZhangChunxiang CaoQi ZhangYi ChenDongying GuYunzhu ShenYongling GongJinfei ChenCuiju TangPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 1, p e84230 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xunlei Zhang Chunxiang Cao Qi Zhang Yi Chen Dongying Gu Yunzhu Shen Yongling Gong Jinfei Chen Cuiju Tang Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
description	<h4>Purpose</h4>Oral fluoropyrimidine (S-1, capecitabine) has been considered as an important part of various regimens. We aimed to evaluate the efficacy and safety of S-1-based therapy versus capecitabine -based therapy in gastrointestinal cancers.<h4>Methods</h4>Eligible studies were identified from Pubmed, EMBASE. Additionally, abstracts presented at American Society of Clinical Oncology (ASCO) conferences held between 2000 and 2013 were searched to identify relevant clinical trials. The outcome included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR) and advent events.<h4>Results</h4>A total of 6 studies (4 RCTs and 2 retrospective analysis studies) containing 790 participants were included in this meta-analysis, including 401 patients in the S-1-based group and 389 patients in the capecitabine-based group. Results of our meta-analysis indicated that S-1-based and capecitabine-based regimens showed very similar efficacy in terms of PFS (HR 0.92, 95% CI 0.78-1.09, P = 0.360), OS (HR 1.01, 95% CI 0.84-1.21, P = 0.949), ORR (HR 1.04, 95% CI 0.87-1.25, P = 0.683) and DCR (HR 1.02, 95% CI 0.94-1.10, P = 0.639). There was also no significant difference in toxicity between regimens other than mild more hand-foot syndrome in capecitabine-based regimens.<h4>Conclusion</h4>Both the S-1-based and capecitabine-based regimens are equally active and well tolerated, and have the potential of backbone chemotherapy regimen in further studies of gastrointestinal cancers.
format	article
author	Xunlei Zhang Chunxiang Cao Qi Zhang Yi Chen Dongying Gu Yunzhu Shen Yongling Gong Jinfei Chen Cuiju Tang
author_facet	Xunlei Zhang Chunxiang Cao Qi Zhang Yi Chen Dongying Gu Yunzhu Shen Yongling Gong Jinfei Chen Cuiju Tang
author_sort	Xunlei Zhang
title	Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
title_short	Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
title_full	Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
title_fullStr	Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
title_full_unstemmed	Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
title_sort	comparison of the efficacy and safety of s-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/05848c7d9c454236951e81ce1291e9c5
work_keys_str_mv	AT xunleizhang comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis AT chunxiangcao comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis AT qizhang comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis AT yichen comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis AT dongyinggu comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis AT yunzhushen comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis AT yonglinggong comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis AT jinfeichen comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis AT cuijutang comparisonoftheefficacyandsafetyofs1basedandcapecitabinebasedregimensingastrointestinalcancerametaanalysis
_version_	1718421481583542272

Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.

Ejemplares similares